Recruiting now—Ages 21 Years and up
A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated With Percutaneous Ablation and Palliative Radiation Therapy
Sponsor: Society of Interventional Oncology · NCT06859801 on ClinicalTrials.gov ↗
Conditions studied
Bone Cancer Metastatic
What it tests
- Percutaneous Ablationdevice
- Radiation Therapyradiation
Where it's running7 sites
- Recruiting now
University of California San Diego Moores Cancer Center
San Diego, California 92093
- Kathy Velasco(contact)858-822-5677[email protected]
- Anthony Tadros, MD(principal investigator)
- Kathryn Tringale, MD(principal investigator)
- Recruiting now
Baptist Health Medical Group
Miami, Florida 33176
- Jetsenea Coto(contact)786-596-7708[email protected]
- Gina Landinez, MD(principal investigator)
- Jean Pierre Obeid, MD(principal investigator)
- Recruiting now
Emory University Hospital
Atlanta, Georgia 30322
- Maria Rivas(contact)404-712-7962[email protected]
- Junjian Huang, MD(principal investigator)
- Rohini Bhatia, MD(principal investigator)
- Recruiting now
Northside Hospital
Atlanta, Georgia 30342
- Shannon Gleason(contact)404-303-3355[email protected]
- Jason Levy, MD(principal investigator)
- Mudit Chowdhary, MD(principal investigator)
- Recruiting now
Mayo Clinic
Rochester, Minnesota 55905
- Desirae Howe-Clayton(contact)507-255-0111[email protected]
- Brian Welch, MD(principal investigator)
- Sean Park, MD(principal investigator)
- Recruiting now
Washington University
St Louis, Missouri 63110
- Addie Lovato(contact)314-362-4263[email protected]
- Resten Imaoka, MD(principal investigator)
- Joanna Yang, MD(principal investigator)
- Recruiting now
Medical College of Wisconsin
Milwaukee, Wisconsin 53226
- Kyersten Hoene(contact)9209796340[email protected]
- Matthew Scheidt, MD(principal investigator)
- Meena Bedi, MD(principal investigator)
See the official eligibility language
Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.
Inclusion Criteria: * 1\. Skeletal metastasis with localized pain not controlled medically \[recall within last 24 hours of worst pain ≥ 5 using the BPI\] * 2\. Pain must be from one painful metastatic lesion involving the bone (additional less painful metastatic sites may be present). Extra-osseous extension of disease is allowed (must have some contact with the bone and be causing bone/tumor interface pain) * 3\. Lesions that are at high-risk of skeletal related events defined as follows: * a. Minimum Spinal Instability Neoplastic Score (SINS) score ≥ 7 for lesions involving the spine * b. Pelvic and appendicular lytic lesions with or without cortical breakthrough causing functional/mechanical pain * 4\. Target lesion amenable to percutaneous ablation with image guidance AND RT by specialists' review * 5\. No prior targeted radiation therapy or ablation to the index lesion * 6\. ECOG performance status 0-2 * 7\. Age ≥ 21 years * 8\. Have signed the current approved informed consent form * 9\. Willing and able to answer follow-up Patient Reported Outcomes (PRO) surveys (e.g., PROMIS®, BPI, COST-FACIT, and OMED) for up to 12 months * 10\. Life expectancy \> 3 months Exclusion Criteria: * 1\. Any medical or personal condition that, in the opinion of the site investigator, may potentially compromise the safety or compliance of the patient, or may preclude the patient's successful completion of the clinical trial. * 2\. Target tumor involves a weight-bearing long bone of the lower extremity with the tumor causing \> 50% loss of cortical bone \[MIREL Score ≥ 7\] * 3\. Skeletal lesions with unstable pathologic fractures requiring immediate surgical stabilization * 4\. Concurrent participation in other studies that could affect the primary endpoint * 5\. Target tumor causing clinical or imaging evidence of spinal cord compression
Updated 2026-06-05 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.